Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

Preferences for human papillomavirus testing with routine cervical cancer screening in diverse older women.

Huang AJ, Pérez-Stable EJ, Kim SE, Wong ST, Kaplan CP, Walsh JM, Iwaoka-Scott AY, Sawaya GF.

J Gen Intern Med. 2008 Sep;23(9):1324-9. doi: 10.1007/s11606-008-0633-x. Epub 2008 May 28.

2.

Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.

Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, Demuth F, Schiffman M, Wacholder S, Castle PE.

Lancet Oncol. 2011 Jul;12(7):663-72. doi: 10.1016/S1470-2045(11)70145-0. Epub 2011 Jun 16. Erratum in: Lancet Oncol. 2011 Aug;12(8):722.

3.

Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.

Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, Ransley JE, Fetterman BJ, Hartinger JS, McIntosh KM, Pawlick GF, Hiatt RA.

JAMA. 1999 May 5;281(17):1605-10.

PMID:
10235153
4.

Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.

Luyten A, Scherbring S, Reinecke-Lüthge A, Braun BE, Pietralla M, Theiler K, Petry KU.

J Clin Virol. 2009 Nov;46 Suppl 3:S5-10. doi: 10.1016/S1386-6532(09)70294-X.

PMID:
20129072
5.

Screening test results associated with cancer diagnoses in 287 women with cervical squamous cell carcinoma.

Li Z, Austin RM, Guo M, Zhao C.

Arch Pathol Lab Med. 2012 Dec;136(12):1533-40. doi: 10.5858/arpa.2011-0609-OA. Epub 2012 Aug 20.

PMID:
22900617
6.

Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data.

Tiews S, Steinberg W, Schneider W, Hanrath C.

J Clin Virol. 2009 Nov;46 Suppl 3:S11-5. doi: 10.1016/S1386-6532(09)70295-1.

PMID:
20129068
7.

Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.

Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M.

J Natl Cancer Inst. 2003 Jan 1;95(1):46-52.

PMID:
12509400
8.

Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.

Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA.

JAMA. 2002 Oct 9;288(14):1749-57.

PMID:
12365959
9.

Human papilloma virus testing knowledge and attitudes among women attending colposcopy clinic with ASCUS/LGSIL pap smears.

Le T, Hicks W, Menard C, Boyd D, Hewson T, Hopkins L, Kee Fung MF.

J Obstet Gynaecol Can. 2004 Sep;26(9):788-92.

PMID:
15361273
10.

MicroRNA detection in cervical exfoliated cells as a triage for human papillomavirus-positive women.

Tian Q, Li Y, Wang F, Li Y, Xu J, Shen Y, Ye F, Wang X, Cheng X, Chen Y, Wan X, Lu W, Xie X.

J Natl Cancer Inst. 2014 Sep 4;106(9). pii: dju241. doi: 10.1093/jnci/dju241. Print 2014 Sep.

11.

Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?

Saraiya M, Berkowitz Z, Yabroff KR, Wideroff L, Kobrin S, Benard V.

Arch Intern Med. 2010 Jun 14;170(11):977-85. doi: 10.1001/archinternmed.2010.134.

PMID:
20548011
12.

Assessing the role of education in women's knowledge and acceptance of adjunct high-risk human Papillomavirus testing for cervical cancer screening.

Papa D, Moore Simas TA, Reynolds M, Melnitsky H.

J Low Genit Tract Dis. 2009 Apr;13(2):66-71. doi: 10.1097/LGT.0b013e31818a53f0.

PMID:
19387125
13.

HPV testing with cytology triage for cervical cancer screening in routine practice.

Louvanto K, Chevarie-Davis M, Ramanakumar AV, Franco EL, Ferenczy A.

Am J Obstet Gynecol. 2014 May;210(5):474.e1-7. doi: 10.1016/j.ajog.2013.12.033. Epub 2013 Dec 25.

PMID:
24373948
14.

Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.

Zorzi M, Del Mistro A, Farruggio A, de'Bartolomeis L, Frayle-Salamanca H, Baboci L, Bertazzo A, Cocco P, Fedato C, Gennaro M, Marchi N, Penon MG, Cogo C, Ferro A.

BJOG. 2013 Sep;120(10):1260-7; discussion 1267-8. doi: 10.1111/1471-0528.12272. Epub 2013 Jun 21.

15.
16.

Screening trial of human papillomavirus for early detection of cervical cancer in Santiago, Chile.

Ferreccio C, Barriga MI, Lagos M, Ibáñez C, Poggi H, González F, Terrazas S, Katki HA, Núñez F, Cartagena J, Van De Wyngard V, Viñales D, Brañes J.

Int J Cancer. 2013 Feb 15;132(4):916-23. doi: 10.1002/ijc.27662. Epub 2012 Jun 26. Erratum in: Int J Cancer. 2013 Jul 15;133(2):E1.

17.

HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer.

Wright TC Jr, Denny L, Kuhn L, Pollack A, Lorincz A.

JAMA. 2000 Jan 5;283(1):81-6.

PMID:
10632284
18.

Cervical Cancer Screening Preferences Among Trans-Masculine Individuals: Patient-Collected Human Papillomavirus Vaginal Swabs Versus Provider-Administered Pap Tests.

McDowell M, Pardee DJ, Peitzmeier S, Reisner SL, Agénor M, Alizaga N, Bernstein I, Potter J.

LGBT Health. 2017 Aug;4(4):252-259. doi: 10.1089/lgbt.2016.0187. Epub 2017 Jun 30.

PMID:
28665783
19.

Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up.

Castle PE, Glass AG, Rush BB, Scott DR, Wentzensen N, Gage JC, Buckland J, Rydzak G, Lorincz AT, Wacholder S.

J Clin Oncol. 2012 Sep 1;30(25):3044-50. doi: 10.1200/JCO.2011.38.8389. Epub 2012 Jul 30.

20.

Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancer.

Gyllensten U, Sanner K, Gustavsson I, Lindell M, Wikström I, Wilander E.

Br J Cancer. 2011 Aug 23;105(5):694-7. doi: 10.1038/bjc.2011.277. Epub 2011 Aug 2.

Supplemental Content

Support Center